EARNINGS (LOSS) PER SHARE (Tables)

12 Months Ended

Dec. 31, 2022

Schedule of Basic and Diluted Earnings (Loss) Per Share

The following table presents the Company’s basic earnings (loss) per share and shares outstanding (in thousands, except per share data):


	Year Ended December 31,
	2022		2021		2020
Numerator:
Net income (loss) (1) (2)	$	150,556	$	139,898	$	(8,076)
Denominator:
Weighted average number of common shares outstanding	181,105		179,855		180,971
Earnings (loss) per Common Share:
Earnings (loss) per common share, basic	$	0.83	$	0.78	$	(0.04)

(1) Net income (loss) for the year ended December 31, 2021 includes the impact of the Company’s release of its valuation allowance. See Note 6, Income Taxes, for further discussion.

(2) Net income (loss) for the year ended December 31, 2022 includes the impact of the Company’s Respiratory Therapy Asset Sale. See Note 3, Business Acquisitions and Divestitures, for further discussion.

The following table presents the Company’s diluted earnings (loss) per share and shares outstanding (in thousands, except per share data):


	Year Ended December 31,
	2022		2021		2020
Numerator:
Net income (loss) (1) (2)	$	150,556	$	139,898	$	(8,076)
Denominator:
Weighted average number of common shares outstanding	181,105		179,855		180,971
Effect of dilutive securities	970		1,350		—
Weighted average number of common shares outstanding, diluted	182,075		181,205		180,971
Earnings (loss) per Common Share:
Earnings (loss) per common share, diluted	$	0.83	$	0.77	$	(0.04)

(1) Net income (loss) for the year ended December 31, 2021 includes the impact of the Company’s release of its valuation allowance. See Note 6, Income Taxes, for further discussion.